MARKET

IDRA

IDRA

Idera Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.130
+0.040
+1.91%
After Hours: 2.130 0 0.00% 16:23 10/22 EDT
OPEN
2.100
PREV CLOSE
2.090
HIGH
2.170
LOW
2.100
VOLUME
68.35K
TURNOVER
--
52 WEEK HIGH
2.950
52 WEEK LOW
0.8130
MARKET CAP
74.97M
P/E (TTM)
-0.8201
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Idera announces patent coverage for tilsotolimod through September 2037
Idera Pharmaceuticals (IDRA) receives patent and is allowed application entitled 'Immune Modulation with TLR9 Agonists for Cancer Treatment' for investigational therapy tilsotolimod.The patents and the allowed application provide exclusivity for certain uses
Seekingalpha · 09/28 13:08
Idera Pharmaceuticals Announces New U.S. Patent Coverage For Tilsotolimod Through Sept. 2037
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037 EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) today announced that the U.S.
Benzinga · 09/28 12:47
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
* Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presented * AbbVie to present a trial-in-progress poster of ABBV-368 in combination with tilsotolimod in recurrent / metastatic head and neck squamous cell carcinoma
GlobeNewswire · 09/15 12:18
Why Idera Pharmaceuticals' (NASDAQ:IDRA) CEO Pay Matters
This article will reflect on the compensation paid to Vinnie, Vin Milano who has served as CEO of Idera...
Simply Wall St. · 09/10 15:13
iBio and Viveve Medical among healthcare gainers; Proteostasis Therapeutics among losers
Gainers: Viveve Medical (VIVE) +113%. Orchard Therapeutics (ORTX) +27%. iBio (IBIO) +16%. Idera Pharmaceuticals (IDRA) +15%. Cutera (CUTR) +14%.Losers: Sonnet BioTherapeutics (SONN) -21%. Cancer Genetics (CGIX) -17%. Liminal BioSciences (LMNL) -16%. Proteostasis Therapeutics (PTI) -15%. Lipocine
Seekingalpha · 08/25 15:06
Idera Pharmaceuticals EPS misses by $0.33
Idera Pharmaceuticals (NASDAQ:IDRA): Q2 GAAP EPS of -$0.72 misses by $0.33. Cash, cash equivalents, and short-term investments of $31M. Shares -2.9% AH. Pr
seekingalpha · 08/05 02:13
Idera Pharma S-3 Filing Shows Registration For ~5.53M Share Common Stock Offering Via Selling Shareholders
Benzinga · 08/04 21:14
Idera Pharmaceuticals Q2 EPS $(0.24) Up From $(0.39) YoY
Idera Pharmaceuticals (NASDAQ:IDRA) reported quarterly losses of $(0.24) per share. This is a 38.46 percent increase over losses of $(0.39) per share from the same period last year.
Benzinga · 08/04 20:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IDRA. Analyze the recent business situations of Idera Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IDRA stock price target is 7.60 with a high estimate of 10.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 85
Institutional Holdings: 11.66M
% Owned: 33.13%
Shares Outstanding: 35.20M
TypeInstitutionsShares
Increased
11
571.62K
New
9
-66.44K
Decreased
10
349.34K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.60%
Pharmaceuticals & Medical Research
+1.05%
Key Executives
Chairman/Independent Director
James Geraghty
Chairman/Independent Director
james Geraghty
President/Chief Executive Officer/Director
Vincent Milano
Chief Financial Officer/Senior Vice President
John Kirby
Senior Vice President/General Counsel/Secretary
Bryant Lim
Senior Vice President
Robert Fletcher
Senior Vice President
Elizabeth Tarka
Independent Director
Cristina Csimma
Independent Director
Michael Dougherty
Independent Director
Mark Goldberg
Independent Director
Maxine Gowen
Independent Director
Carol Schafer
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IDRA
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Idera Pharmaceuticals Inc stock information, including NASDAQ:IDRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDRA stock methods without spending real money on the virtual paper trading platform.